Can clinical and molecular epidemiologic parameters guide empiric treatment with vancomycin for methicillin-resistant Staphylococcus aureus infections?

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 1, 2011, Pages 124-130

  Yamaki, Jason ^a   Lee, Michelle ^b   Shriner, Kimberly A ^b   Wong Beringer, Annie ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

MRSA; PVL; Resistance; Susceptibility; Vancomycin

Indexed keywords

DAPTOMYCIN; LINEZOLID; TIGECYCLINE; VANCOMYCIN;

AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COHORT ANALYSIS; COMMUNICABLE DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; EPSILOMETER TEST; FEMALE; GENETIC ANALYSIS; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PANTON VALENTINE LEUKOCIDIN GENE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCAL CASSETTE CHROMOSOME MEC ELEMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; DNA, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 79955019812     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.12.003     Document Type: Article

References (32)

1. Anon Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care 2005, 171:388-416.
2. Bonnstetter K.K., Wolter D.J., Tenover F.C., McDougal L.K., Goering R.V. Rapid multiplex PCR assay for identification of USA300 community-associated methicillin-resistant Staphylococcus aureus isolates. J. Clin. Microbiol. 2007, 45:141-146.
3. Boye K., Bartels M.D., Andersen I.S., Moller J.A., Westh H. A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCCmec types I-V. Clin. Microbiol. Infec. 2007, 13:725-727.
4. Chua T., Moore C.L., Perri M.B., Donabedian S.M., Masch W., Vager D., Davis S.L., Lulek K., Zimnicki B., Zervos M.J. Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J. Clin. Microbiol. 2008, 46:2345-2352.
5. Community Associated MRSA Information for Clinicians Infection control topics, Centers for Disease Control and Prevention Available at, Accessed 24 June 2010. http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_clinicians.html.
6. Cui L.Z., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Ch. 2006, 50:1079-1082.
7. Davis S.L., Rybak M.J., Amjad M., Kaatz G.W., McKinnon P.S. Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect. Control Hosp. Ep. 2006, 27:1025-1031.
8. De Lencastre H., Oliveira D., Tomasz A. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr. Opin. Microbiol. 2007, 10:428-435.
9. Graber C.J., Wong M.K., Carleton H.A., Perdreau-Remington F., Haller B.L., Chambers H.F. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg. Infect. Dis. 2007, 13:491-493.
10. Guintu R.C., et al. Rapid identification/detection of Panton-Valentine leukocidin (PVL) gene in Staphylococcus aureus using PVL EVIGENE™ (AdvanDx) 2006.
11. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections-efficacy and toxicity. Arch. Intern. Med. 2006, 166:2138-2144.
12. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 2008, 36:309-332.
13. Huang H., Flynn N.M., Kim J.H., Monchaud C., Morita M., Cohen S.H. Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. J. Clin. Microbiol. 2006, 44:2423-2427.
14. Jevitt L.A., Smith A.J., Williams P.P., Raney P.M., McGowan J.E., Tenover F.C. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb. Drug Resist-Mech. Epidemiol. Dis. 2003, 9:389-393.
15. Jones T., Yeaman M.R., Sakoulas G., Yang S.J., Proctor R.A., Sahl H.G., Schrenzel J., Xiong Y.Q., Bayer A.S. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 2008, 52:269-278.
16. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., Craig A.S., Zell E.R., Fosheim G.E., McDougal L.K., Carey R.B., Fridkin S.K. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
17. Limbago B.A., Fosheim G.E., Carey R.B. Evaluation of the AdvanDx PVL EVIGENE™ kit for use detecting the PVL locus in Staphylococcus aureus 2006.
18. Liu C., Graber C.J., Karr M., Diep B.A., Basuino L., Schwartz B.S., Enright M.C., O'Hanlon S.J., Thomas J.C., Perdreau-Remington F., Gordon S., Gunthorpe H., Jacobs R., Jensen P., Leoung G., Rumack J.S., Chambers H.F. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin. Infect. Dis. 2008, 46:1637-1646.
19. Maree C.L., Daum R.S., Boyle-Vavra S., Matayoshi K., Miller L.G. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg. Infect. Dis. 2007, 13:236-242.
20. Musta A.C., Riederer K., Shemes S., Chase P., Jose J., Johnson L.B., Khatib R. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 2009, 47:1640-1644.
21. Naimi T.S., LeDell K.H., Como-Sabetti K., Borchardt S.M., Boxrud D.J., Etienne J., Johnson S.K., Vandenesch F., Fridkin S., O'Boyle C., Danila R.N., Lynfield R. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003, 290:2976-2984.
22. Patel J.B., Jevitt L.A., Hageman J., McDonald L.C., Tenover F.C. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 2006, 42:1652-1653.
23. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R., Craig W., Billeter M., Dalovisio J.R., Levine D.P. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 2009, 66:82-98.
24. Sader H.S., Jones R.N., Rossi K.L., Rybak M.J. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J. Antimicrob. Chemother. 2009, 64:1024-1028.
25. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 2004, 42:2398-2402.
26. Sanchez Garcia M., De la Torre M.A., Morales G., Pelaez B., Tolon M.J., Domingo S., Candel F.J., Andrade R., Arribi A., Garcia N., Martinez Sagasti F., Fereres J., Picazo J. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303:2260-2264.
27. Seybold U., Kourbatova E.V., Johnson J.G., Halvosa S.J., Wang Y.F., King M.D., Ray S.M., Blumberg H.M. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 2006, 42:647-656.
28. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., Alamo D., Ortega M., Lopez J., Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2008, 46:193-200.
29. Styers D., Sheehan D.J., Hogan P., Sahm D.F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 2006, 5:2.
30. Vandenesch F., Naimi T., Enright M.C., Lina G., Nimmo G.R., Heffernan H., Liassine N., Bes M., Greenland T., Reverdy M.E., Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 2003, 9:978-984.
31. Wootton M., MacGowan A.P., Walsh T.R. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob. Agents Ch. 2006, 50:4195-4197.
32. Zetola N., Francis J.S., Nuermberger E.L., Bishai W.R. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet. Infect. Dis. 2005, 5:275-286.